American Academy of Dermatology

Integrative, Allopathic Approaches Add Options for Pediatric AD
May 04, 2022

Allergic contact dermatitis and atopic dermatitis are common causes of rashes in the pediatric population. Patch testing can help demystify the cause of such skin conditions and determine treatment.

Phase 2 EDP1815 Data for Psoriasis Released
April 08, 2022

The results from the Evelo Biosciences EDP1815 treatment provide the first demonstration in a phase 2 trial of the safety and efficacy of an orally-administered, gut-restricted SINTAX medicine.

New Long-Term Safety, Efficacy Data for Adbry in Moderate to Severe AD
April 07, 2022

LEO Pharma presented long-term data from an interim analysis of its ECZTEND 5-year extension trial, showing no new safety signals.

Post- and Pre-lightening Procedures
April 05, 2022

What are the best post- and pre-lightening products and strategies for optimal results on all skin types? Renata Block, president of the Society of Dermatology Physician Assistants, walked through her pearls in this interview at the American Academy of Dermatology 2022 Annual Meeting.

PAs Play Role in Increased Accessibility to Dermatologic Care
April 04, 2022

Renata Block, MMS, PA-C, president of the Society of Dermatology Physician Assistants (PAs) talked with Dermatology Times® at the American Academy of Dermatology 2022 Annual Meeting about the broadening opportunities for these advanced health care providers to help fill the demand gap for treatment of skin and hair disorders as well as aesthetic services.

Poster: Real-World Experience of Dupilumab Treatment in AD
April 01, 2022

A poster from the 2022 American Academy of Dermatology Annual Meeting gathered the real-world data around patients using dupilumab to treat atopic dermatitis.

Efficacy of Spesolimab for GPP Flare Treatment
April 01, 2022

A poster from the 2022 American Academy of Dermatology Annual Meeting presented subgroup analyses from the Effisayil 1 study that showed the efficacy of spesolimab was consistent across all prespecified patient populations, including those with or without IL-36RN mutations.

Art Papier, MD, on Skin of Color Imagery
April 01, 2022

VisualDX uses diverse imagery to help increase knowledge of disease manifestations in a range of skin types.

What's Up and Coming in MCC
April 01, 2022

In this fourth part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, talks about what to look forward to in treatment and clinical trials of merkel cell carcinoma (MCC).

Clinical Experiences of Using Circulating Tumor DNA
April 01, 2022

In this third part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, highlights the in practice experiences in using circulating tumor DNA for merkel cell carcinoma (MCC).